Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Read now
Alberto Bretoni, Lucrezia Ferrario & Emanuela Foglia. (2019) HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer. ClinicoEconomics and Outcomes Research 11, pages 283-300.
Read now
Read now
Yazan K. Barqawi, Matthew E. Borrego, Melissa H. Roberts & Ivo Abraham. (2019) Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. Journal of Medical Economics 22:11, pages 1202-1209.
Read now
Read now
Yusuke Ito & Marianne D Sadar. (2018) Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology 10, pages 23-32.
Read now
Read now
Randi Fuglsang Fonager, Helle Damgaard Zacho, Niels Christian Langkilde, Joan Fledelius, June Anita Ejlersen, Helle Westergreen Hendel, Christian Haarmark, Mette Moe, Jesper Carl Mortensen, Mads Ryø Jochumsen & Lars Jelstrup Petersen. (2018) Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. Acta Oncologica 57:8, pages 1063-1069.
Read now
Read now
Hiroji Uemura, Marco DiBonaventura, Ed Wang, Dianne Athene Ledesma, Kristen Concialdi & Yasuko Aitoku. (2017) The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 511-517.
Read now
Read now
Marjan Massoudi, Mark Balk, Hongbo Yang, Cat N. Bui, Bhavik J. Pandya, Jenny Guo, Yan Song, Eric Q. Wu, Bruce Brown, Arie Barlev & Scott Flanders. (2017) Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Journal of Medical Economics 20:2, pages 121-128.
Read now
Read now
Articles from other publishers (14)
Rémi Pelloux-Prayer, Thomas Bataillard, Antoine Thiery-Vuillemin, Alexandre Vincent, Philippe Fagnoni & Virginie Nerich. (2022) Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations. Clinical Genitourinary Cancer 20:6, pages 594-602.
Crossref
Crossref
Dorota Danielak, Tereza Krejčí & Josef Beránek. (2022) Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. European Journal of Pharmaceutical Sciences 176, pages 106254.
Crossref
Crossref
Yash B. Shah, Amy L. Shaver, Jacob Beiriger, Sagar Mehta, Nikita Nikita, William Kevin Kelly, Stephen J. Freedland & Grace Lu-Yao. (2022) Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review. Cancers 14:15, pages 3773.
Crossref
Crossref
Rémi Pelloux-Prayer, Philomène Schiele, Stéphane Oudard, Gwenaëlle Gravis, François Kleinclauss, Gilles Crehange, Christophe Hennequin, Alicia K. Morgans, Lionel Geoffrois, Samuel Limat, Antoine Thiery-Vuillemin & Virginie Nerich. (2021) Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clinical Genitourinary Cancer 19:5, pages e326-e333.
Crossref
Crossref
Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono & Maarten IJzerman. (2021) Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus 7:4, pages 752-763.
Crossref
Crossref
Michaela A. Dinan, Gary H. Lyman, Richard L. Schilsky & Daniel F. Hayes. (2019) Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology:3, pages 1-10.
Crossref
Crossref
M. Koninckx, J. L. Marco, I. Pérez, M. T. Faus, V. Alcolea & F. Gómez. (2018) Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clinical and Translational Oncology 21:3, pages 314-323.
Crossref
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Crossref
Neil M. Schultz, Scott C. Flanders, Samuel Wilson, Bruce A. Brown, Yan Song, Hongbo Yang, Stanislav Lechpammer & Vahan Kassabian. (2018) Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. Advances in Therapy 35:10, pages 1639-1655.
Crossref
Crossref
Russell Z. SzmulewitzCody J. PeerAbiola IbraheemElia MartinezMark F. KozloffBradley CarthonR. Donald HarveyPaul FishkinWei Peng YongEdmund ChiongChadi NabhanTheodore KarrisonWilliam D. FiggWalter M. StadlerMark J. Ratain. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology 36:14, pages 1389-1395.
Crossref
Crossref
Jan Norum & Carsten Nieder. (2017) Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. PharmacoEconomics 35:12, pages 1223-1236.
Crossref
Crossref
Paul B. JacobsenRyan D. NippPatricia A. Ganz. (2017) Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. American Society of Clinical Oncology Educational Book:37, pages 674-683.
Crossref
Crossref
Randi F. Fonager, Helle D. Zacho, Signe Albertsen, Joan Fledelius, June A. Ejlersen, Mette H. Christensen, Ramune Aleksyniene, José A. Biurrun Manresa & Lars J. Petersen. (2017) Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients. Nuclear Medicine Communications 38:3, pages 215-221.
Crossref
Crossref
Anthony Barron & Tim Wilsdon. (2016) Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer. Pharmaceutical Medicine 30:6, pages 321-326.
Crossref
Crossref